Interchangeable Biosimilar Approval: FDA Greenl...

By João L. Carapinha

November 17, 2025

FDA Grants First Interchangeable Biosimilar Approval for HER2-Positive Breast Cancer Treatment The U.S. Food and Drug Administration (FDA...
Weight Loss: Advances in Hormone-Based Obesity Treatments
CTX310 Lipid Disorder: Phase 1 Trial Shows Promising LDL and Triglyceride Red...
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...
Eloralintide Obesity Treatment: Phase 2 Trial Reveals Significant Weight Loss...
Accelerated UK Clinical Trial Reforms: Enhancing Approvals with AI and Effici...
AI in South African Healthcare: Professionals’ Confidence in Reducing A...
AI Chatbot Delusions: Navigating the Risks of Validation in Mental Health
Challenging the Narrative: Pharmaceutical Innovation Funding and Its Complex ...
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
Fabhalta Kidney Treatment Shows Promise in Slowing Disease Progression for Ig...
Tukysa Breast Cancer Therapy Boosts Progression-Free Survival in Advanced Cases
Datroway TNBC Therapy: Transforming First-Line Treatment for Metastatic Tripl...